Skip to content
Review Open access

[177Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing

Oct 2026 · Current Oncology · Vol 33, pp. 624 · 0 citations · 46 references
Medicine

TL;DR

Radioligand therapy delivers radiation to prostate cancer cells that express a protein called prostate-specific membrane antigen (PSMA) that delayed worsening on scans or death, but increased side effects, including severe adverse events and dry mouth.

Abstract

Simple Summary Radioligand therapy delivers radiation to prostate cancer cells that express a protein called prostate-specific membrane antigen (PSMA). PSMAddition tested adding this treatment to hormonal therapy earlier in patients whose cancer had spread but still responded to hormone treatment. Published results showed that it delayed worsening on scans or death, but increased side effects, including severe adverse events and dry mouth. Longer follow-up is needed to determine whether patients live longer. Quality-of-life and pain worsening endpoints did not differ significantly between groups; this does not establish equivalent wellbeing or absence of harm. Some patients initially assigned to hormonal therapy alone received radioligand therapy after progression, but later treatment was not guaranteed. This review considers the trial alongside other treatments, scan findings, patients’ general health, future treatment options, and access to specialist services. It offers a framework to help clinical teams and patients discuss these choices.

Read PDF

Similar papers

Open access Oct 2026

Real-World Outcomes of 177Lu-PSMA-617 Radioligand Therapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer

Objective: Among recently developed treatment strategies for advanced prostate cancer, 177Lu-PSMA-617–based radioligand therapy has shown considerable clinical potential in patients with metastatic castration-resistant disease. However, predictors of treatment response and survival outcomes remain incompletely defined....

Ebru Karcı, T. Atasever, Tansel Çakır et al. · 0 citations
Review Open access Oct 2026

PSMA Biology Through the Clinical Lens: Implications for Radioligand Therapy of Prostate Cancer with [177Lu]Lu-PSMA-617.

Prostate cancer remains a leading cause of cancer-related mortality in men worldwide. While hormone therapy is effective in the early stages of advanced disease, multimodal approaches are often required as disease progresses, including radiotherapy, hormonal agents and chemotherapy. In metastatic castration-resistant p...

M. Del Re, M. Bauckneht, R. Danesi · 0 citations
Open access Sep 2026

Combinatorial Treatment Strategy of 177 Lu-PSMA-617 and Docetaxel Chemotherapy in Highly PSMA- and FDG-Avid (Pro-PET Score 3) Metastatic Castration-Resistant Prostate Cancer While Considering Pre-taxane PRLT

Abstract 177 Lu-PSMA-617 targeted radioligand therapy (RLT) received U.S. Food and Drug Administration approval in 2022 for metastatic castration-resistant prostate cancer (mCRPC) patients progressing after androgen receptor pathway inhibitors and taxane chemotherapy. Despite its efficacy, response rates vary, promptin...

Amal Paul, Keerti Sitani, Sandip Basu · 0 citations
Review Open access Sep 2026

PSMA-targeted radioligand therapy with beta emitters in prostate cancer: current evidence, emerging indications, combination strategies, and future directions

Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) has emerged as a major therapeutic advance in metastatic castration-resistant prostate cancer (mCRPC), The phase III VISION trial demonstrated that [177Lu]Lu-PSMA-617 significantly improves overall survival and radiographic progression-free su...

H. Noamen, A. Bekkhoucha, A. Bernard-Tessier et al. · 0 citations
Review Sep 2026

Kidney impairment post 177Lu-PSMA radioligand therapy in metastatic prostate cancer.

Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is a novel theranostic approved for the treatment of metastatic castration-resistant prostate cancer. It has been understood to have a low risk of mild nephrotoxicity, although the emergence of delayed or acute renal toxicity is variably descr...

Jesse Osbourne, M. S. Hofman, Irene Ruderman · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.